Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 802 of 6351
-
Supercharged immune cells take on tough lymphoma
Disease control Recruiting nowA Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma
Early phase 1 • Sponsor: He Huang • Aim: Disease control
Last updated Jun 26, 2026 19:06 UTC
-
New combo therapy aims to boost immune attack on liver tumors
Disease control Recruiting nowAtezolizumab (anti-programmed death-ligand 1; anti-PD-L1) in conjunction with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) has become the established standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). Despite an improved ob…
Phase 2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for Late-Stroke patients: clot removal may work even days later
Disease control CompletedThe aim of this study is to assess the efficacy and safety of endovascular treatment versus medical management in patients with acute basilar artery occlusion with extended time window of 24-72 hours from onset.
Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New combo shows promise against Hard-to-Treat breast cancer
Disease control CompletedThe purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-neg…
Phase 2 • Sponsor: Carrick Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can a clot-busting procedure help stroke patients with prior disabilities?
Disease control Recruiting nowTESTED will compare the risks and benefits of endovascular thrombectomy (EVT) to medical management (no EVT) in ischemic stroke patients who have a blockage in one of the large blood vessels in the brain and have a moderate-to-severe disability prior to their stroke.
Sponsor: University of Cincinnati • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New program aims to prevent lymphedema in breast cancer patients
Prevention Recruiting nowThe purpose of this study to test whether a comprehensive program may help the lymph fluid to drain out of the arm and prevent lymphedema in participants with breast cancer.
Phase 3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 07:56 UTC
-
New hope for advanced breast cancer: OP-1250 faces off against standard care
Disease control OngoingThis phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inh…
Phase 3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Brain wave tool may predict awakening in coma patients
Knowledge-focused Recruiting nowEvaluating the prognosis of comatose patients after cardiac arrest (CA) in the intensive care unit (ICU) remains challenging. It requires a multimodal approach combining standardized clinical examination, serum biomarkers, imaging and classically electrophysiological examinations…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
New COVID booster shows promise in trial
Vaccine CompletedThis is a phase IIb/III, double-blind, randomised, active-controlled, multi-centre, non-inferiority clinical trial that aims to determine safety, tolerability and immunogenicity of a booster vaccination with a recombinant protein receptor binding domain (RBD) fusion homodimer of …
Phase 2/3 • Sponsor: Hipra Scientific, S.L.U • Aim: Vaccine
Last updated Jun 27, 2026 11:01 UTC
-
Breakthrough device could save babies stuck in birth canal
Disease control Recruiting nowProspective, multi-center, single arm with historical control, to verify the safety and effectiveness of the Yaari Extractor used by board certified or board eligible U.S. OB/GYN physicians in the management of shoulder dystocia.
Sponsor: FetalEase Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Spinal zap plus robot suit boosts walking recovery in new trial
Symptom relief OngoingThe goal of this clinical trial is to investigate the effects of transcutaneous spinal cord stimulation (TSCS) combined with exoskeleton training, as compared to exoskeleton training alone to improve motor function in individuals with incomplete spinal cord injury who are 12 mont…
Sponsor: Craig Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
New RA pill takes on tofacitinib in Head-to-Head trial
Disease control OngoingA randomized, double-blind, double-dummy, positive-controlled, phase 3 study to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subjects who had an inadequate response or intolerance to Biologic DMARDs.
Phase 3 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Promising drug may reduce eye bulging in thyroid disease
Disease control CompletedThe purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control OngoingThis is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis. The estimated duration is…
Phase 2 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Botox for jaw pain: a shot at rewiring pain signals?
Disease control Recruiting nowThe goal of this clinical trial is to investigate the effect of botulinum toxin on neurons' plasticity in the masseter muscle in humans with and without painful myogenous temporomandibular disorders (TMDM). The main questions it aims to answer are: * does treatment with botulinu…
Phase 2 • Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug cocktail aims to shrink tough head and neck tumors
Disease control OngoingThe primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill aims to quiet hallucinations in Alzheimer's patients
Symptom relief Recruiting nowThis is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP * Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This subs…
Phase 2/3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
New drug aficamten shows promise for thick heart muscle in chinese patients
Disease control CompletedThis is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac function and steady-state Pharmacokinetics (PK) during…
Phase 3 • Sponsor: Corxel Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug combo targets hard-to-treat cancers with KRAS mutation
Disease control Recruiting nowThis study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Phase 1/2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug combo shows promise in lymphoma battle
Disease control OngoingThis study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participants with follicular lymphoma t…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC